March 1, 2016



Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., March 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2015 financial results after market close on Tuesday, March 8, 2016. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 54348262. The conference call will also be webcast live and can be accessed from Rigel's website at <u>www.rigel.com</u>. The webcast will be archived and available for replay for 30 days after the call via the Rigel website.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for lgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Raul Rodriguez Phone: 650.624.1302 Email: <u>invrel@rigel.com</u>

Media Contact: Susan C. Rogers, Rivily, Inc. Phone: 650.430.3777 Email: <u>susan@rivily.com</u>

Logo - https://photos.prnewswire.com/prnh/20030226/RIGLLOGO

To view the original version on PR Newswire, visit<u>http://www.prnewswire.com/news-</u> releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-yearend-2015-financial-results-300228379.html

SOURCE Rigel Pharmaceuticals, Inc.